{"section": [{"title": "Remarks by Lawrence Biegelsen", "id": 1, "section": [{"id": 2, "text": "I wanted to ask one on 2023, just a framework and some things to consider and then one on tricuspid, Mike and Scott. Just starting with 2023, I think people are going to look at the second half implied growth year, call it, 7% by my math. And maybe there'll be -- maybe that will raise some concerns about growth next year. So Mike, can you provide some framework for how to think about '23? Any catalyst to call out and stop P&L considerations that we should take into account? I heard the FX headwind, the 250 basis points, just any high-level thoughts given the shortfall last quarter and this quarter? And I had one follow-up.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Lawrence Biegelsen\", \"section_number\": 1, \"uuid\": \"af8b92e9-03df-440a-875c-e77676ab0278\", \"speaker_title\": \"Analyst at Wells Fargo Securities\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 3, "section": [{"id": 4, "text": "So Larry, it's Scott. Why don't I start with the financial piece of that and then turn it over to Mike to talk about some of the strategic things that we expect in 2023. Financially, we haven't gotten into the quarter-by-quarter FX impact or growth rates. Typically, we don't give guidance, as you know, for the next year until our investor conference. We'll give you more details then. But just we thought it was helpful because FX has been such an impact this year and it will continue to fall over the next year that will help quantify what the top line impact will be which we think is near what is going to be this year.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 2, \"uuid\": \"d11de9c0-114d-48a5-adb3-10cc4ab0676d\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}, {"id": 5, "text": "So this year, we're at like 5% of sales and about $270 million. We think maybe it gets near to that at current rates, when we forecast for 2023 but we don't have the quarter-by-quarter breakout yet. Mike, do you want to talk about next years...", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Scott Ullem\", \"section_number\": 2, \"uuid\": \"d11de9c0-114d-48a5-adb3-10cc4ab0676d\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 6, "section": [{"id": 7, "text": "Well, I'd just briefly just go through the portfolio. I mean, we feel like the business -- we don't talk about very much like Surgical and Critical Care are strong and are going to continue to deliver. We're going to see catalysts coming from TMTT as we see a lift coming from the introduction of PRECISION next year. And then TAVR, even though we're suffering right now from some staffing shortages, we think those are going to get gradually better. And I expect solid performance. I mean, we're not kidding when we say we still believe that there's a $10 billion opportunity in 2028. We're highly confident in that and I think we're on a path to achieve it.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 3, \"uuid\": \"224f3ab4-48ca-4aad-b654-99fc558d957a\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Lawrence Biegelsen", "id": 8, "section": [{"id": 9, "text": "That's helpful. Mike. And actually, I wanted to ask about tricuspid. A lot of excitement around tricuspid. I know you know that you employed a Bayesian design for Class IID. Is it reasonable to assume that you'll employ a similar design [Phonetic] for your tricuspid pivotal trials, the 2 you mentioned? And just how are you thinking about that opportunity? Our check suggested it should be bigger than mitral, maybe somewhere between mitral and aortic.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Lawrence Biegelsen\", \"section_number\": 4, \"uuid\": \"a226569a-204a-4749-a40f-8b6b0791dece\", \"speaker_title\": \"Analyst at Wells Fargo Securities\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 10, "section": [{"id": 11, "text": "Yes. Thanks, Larry. We're obviously excited about our pipeline and we work very closely with regulators around the world, including the FDA. We typically just don't comment on some of the real specifics of the regulatory process because they tend to change and be situational. And so I'm not going to really get into -- are we going to do on a specific upcoming trial? I mean, we're well aware of all the tools that are available and we'll try and do the smartest thing and work really in a legal fashion with the regulators but it's not clear. I don't know, Bernard, do you have anything you want to add to that?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 5, \"uuid\": \"4f933734-93cc-4c10-ba2f-e02fb253851c\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 12, "section": [{"id": 13, "text": "Yes. Just a small thing. Obviously, any study, any trial has different design. Some are comparing devices together, some are comparing a device to medical treatment. So obviously, it is not as easy as taking what we did for IID and applying that to the other studies.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 6, \"uuid\": \"5bbdfa96-2f62-4c65-8979-adb27f043ede\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Robert Marcus", "id": 14, "section": [{"id": 15, "text": "Maybe first, I think it would be helpful. Maybe walk us through some of the differences between why TAVR so much more impacted than the Surgical business? I know it's lots of similarities but also differences. Is it just pure staffing? Is it the imaging? Is it the testing? Is it the patient pipeline? Any ideas there? And how should we think about the impact from the shortfall in Japan? It looks like numbers came in below the Street by about $15-plus million. Is that all Japan?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert Marcus\", \"section_number\": 8, \"uuid\": \"521e965c-30d6-4c13-93b0-dd8da89690bf\", \"speaker_title\": \"Analyst at JPMorgan Chase & Co.\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 16, "section": [{"id": 17, "text": "Yes. So let me kick it off, Robbie and then I'll turn to Larry and Daveen to supplement the answer. So actually, the TAVR procedures, we believe grew faster than the Surgical procedures, if you look at what the market did in the quarter. When you look at Edwards itself, it looks like the Surgical business was growing faster but that's more Edwards-specific performance rather than what was going on in the underlying market. So I think we have to be a little cautious. Daveen, do you want to add anything from a surgical perspective? And then we'll kick it over to Larry.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 9, \"uuid\": \"46cb93ec-a35c-4e3e-87a7-5832cf86f5aa\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Daveen Chopra", "id": 18, "section": [{"id": 19, "text": "Yes, sure, Mike. I appreciate that. Yes, so to follow up what Mike was saying, Robbie, the growth driver of the Surgical business, as Mike had mentioned, was really about driving adoption of the Brazilian portfolio globally as well as the U.S. launch of our new mitral valve MITRIS which provided a nice uplift. So RESILIA and MITRIS were really our top drivers. But as like I said, we also had a little bit of market growth coming from us -- maybe low single-digit market growth. And we're generally seeing that within the world of surgical operating rooms and surgery beyond cardiac surgery. Cardiac surgery being an area that surgical operating rooms kind of prioritize resources to a surgical operating rooms. So we generally see that led to that slow-low single-digit kind of market growth.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Daveen Chopra\", \"section_number\": 10, \"uuid\": \"4d9a6335-3316-4470-8caf-1fc45ab1e1e1\", \"speaker_title\": \"Corporate Vice President of Surgical Heart Valve Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 20, "section": [{"id": 21, "text": "Yes. This is Larry. As it relates to TAVR, there's more upfront work that has to happen with a TAVR patient than a surgical patient, both in terms of the imaging that has to be done, you have to do a CT for sizing. Oftentimes, you need to do angiograms to screen out for coronary disease so that you can do all of your TAVR case planning. So there's typically more workup that has to be done for a surgical patient. And so when we talk about staffing issues, a staffing issue at any link in the chain can cause patients to move a little bit slower through the system and take a little longer to recover.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 11, \"uuid\": \"500b15d9-e048-4c8f-bb31-9cec4f75677b\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 22, "text": "So I think that's one of the differences we see. But as Mike said, procedures grew faster than surgery. So it's -- and a lot of the growth drivers in surgery, I think, go beyond aortic procedures.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 11, \"uuid\": \"500b15d9-e048-4c8f-bb31-9cec4f75677b\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 23, "section": [{"id": 24, "text": "Yes. And Robbie, just to quickly comment on Japan. Yes, the total impact in the shortfall was only from COVID. COVID hit hard. I don't know how close you were to how hard it hit in Japan but it is hard. And we are doing great in Japan and we continue to do great in Japan. But we really felt the impact of that. It was probably worse towards the middle of the quarter and it started getting better. So it's -- the wave is kind of passing now, if you will. So it's not continuing. But when it hit, it hit in a pretty significant way.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 12, \"uuid\": \"1febb6ca-b993-4140-8ad8-b6c60a49f42b\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Robert Marcus", "id": 25, "section": [{"id": 26, "text": "That's good to know. Maybe one more follow-up question here. The opex control in the quarter was some of the most severe we've seen probably since and ever second and third quarter of 2020 during the worst of COVID. How should we be thinking about where these pullbacks came from -- how sustainable they are? And how fast it could pick up going forward?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Robert Marcus\", \"section_number\": 13, \"uuid\": \"0cf5da2f-812f-416f-b899-d6a265688a8c\", \"speaker_title\": \"Analyst at JPMorgan Chase & Co.\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 27, "section": [{"id": 28, "text": "Yes. Thanks for the question, Robbie. Part of this was operating with a healthy sense of discipline about making sure we're running the company efficiently. But a lot of it was just the benefit of expenses that we incur overseas that translate into lower U.S. dollars.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 14, \"uuid\": \"eb8cdf40-0e27-4ef2-80e3-300f501f018a\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Vijay Kumar", "id": 29, "section": [{"id": 30, "text": "Maybe my first one is, Mike, for you, specifically on U.S. TAVR. I think that $850 million Q4, what's the underlying implied TAVR? Is that low singles? And I think you mentioned 50% of centers in the U.S. grew double digits. I'm curious, is that a comment just to assure people that this market is still double-digit growing? And perhaps the remaining half of the center, you're seeing some of these staffing challenges. Just give us some context on why we're seeing double-digit growth in some centers and not in perhaps the others?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Vijay Kumar\", \"section_number\": 16, \"uuid\": \"ccde7aac-1221-447f-b19f-d221b0bb53d4\", \"speaker_title\": \"Analyst at Evercore ISI\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 31, "section": [{"id": 32, "text": "Yes. I guess we need to check the numbers. I don't know that low single makes sense to me, Vijay. But nonetheless, let's just get into what's there and I'll turn it over to Larry here in a second. But yes, indeed, we saw a great variance across the country in terms of how hospitals have been performing. And Larry could probably give us some color on that. But we saw some centers that were really growing significantly. We mentioned how many had double-digit growth and other centers that just weren't growing at all. But Larry, why don't you get into that a little bit.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 17, \"uuid\": \"d4509126-d795-4efb-af8f-bbb6aac68bad\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 33, "section": [{"id": 34, "text": "Yes. When we looked across the country, I think anywhere we go and anybody we talk to, they talk about staffing challenges. And I think that's pretty consistent across the country. But clearly, it seems to be impacting certain areas of the country more than others. I mean, just anecdotally [indecipherable] centers in Texas in the middle of the country that were growing very, very well. And some of our big programs and more of the urban areas, the population density areas. They were a little bit flatter. And so we do see big differences but it actually -- it encourages me that as these things start to wane, the patients are there. And I think, again, anecdotally, we hear backlogs continue to grow but I think there's still some challenges in working through these staffing issues.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 18, \"uuid\": \"50d4c1c5-4b1e-4362-b33c-14d60d0da7cc\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Vijay Kumar", "id": 35, "section": [{"id": 36, "text": "Understood. And maybe, Scott, one for you. I think that you have $2 billion of cash on the balance sheet. Why not announce a big ASR? I think your peer has done this. Just [indecipherable] that Edwards still believes in the long-term underlying growth of TAVR markets. Clearly, there's some nervousness [indecipherable] guide cut this evening?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Vijay Kumar\", \"section_number\": 19, \"uuid\": \"18a94238-d664-4baf-a3ca-5a91467ca080\", \"speaker_title\": \"Analyst at Evercore ISI\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 37, "section": [{"id": 38, "text": "Well, you're right. We have a lot of cash on the balance sheet. It gives us flexibility to invest for future growth. And so part of that is building additional physical infrastructure, supporting plant production capacity. Part of it is making sure that we're -- ability that we're able to fund external growth. And then yes, we're going to continue to buy back shares. And we've done accelerated share repurchases, including earlier this year. In total this year, it's been our biggest share repurchase year ever at over $800 million.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 20, \"uuid\": \"bec4507e-b119-48d2-a83c-c881c0f6f7cd\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}, {"id": 39, "text": "And so the only good thing about the stock price haven't been under pressure this year is it's given us a chance to go buy in shares and we think that, that's going to be a great long-term investment. We're going to continue to look for opportunities to do that.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Scott Ullem\", \"section_number\": 20, \"uuid\": \"bec4507e-b119-48d2-a83c-c881c0f6f7cd\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Joshua Jennings", "id": 40, "section": [{"id": 41, "text": "Hoping to just ask about U.S. TAVR growth and potential return to the CAGR that I believe is ingrained in the $10 billion by 2028 TAM calculation. I mean do we -- do you think that U.S. TAVR return to double-digit growth requires indication expansion? Is that essential? Or could we see a return to double-digit growth prior to early TAVR opening up the asymptomatic indication and PROGRESS opening up to symptom moderate?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joshua Jennings\", \"section_number\": 22, \"uuid\": \"19bf234e-2ec7-4df7-a967-a3ed5e134ac5\", \"speaker_title\": \"Analyst at Cowen & Company\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 42, "section": [{"id": 43, "text": "Larry, why don't you take that?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 23, \"uuid\": \"7ca9a62b-24b9-4c81-a1b4-ee91ed38d829\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 44, "section": [{"id": 45, "text": "Yes. Thanks, Josh. There's -- just because of the nature of the trials and the 2-year end points that we have on these trials, they're not really big contributors to those numbers. And what drives those numbers is we still have only about 1 out of 10 patients with aortic stenosis that are getting treated in the U.S. And if you look at the penetration rates, outside the U.S., they're much smaller than that. I mean, in a lot of Rest of World places, they're just really just getting started and Japan is very undertreated.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 24, \"uuid\": \"c383d0d6-e48c-41f9-86ce-56390a636cab\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 46, "text": "So I think it's just a matter of getting through some of this COVID lag that we've had, getting some of the staffing a little bit healthier. And then I think it's going to return back to normal. I sort of see the indication expansion as being things that give us legs beyond the $10 billion.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 24, \"uuid\": \"c383d0d6-e48c-41f9-86ce-56390a636cab\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Joshua Jennings", "id": 47, "section": [{"id": 48, "text": "Great. And just a follow-up on the RESILIA tissue incorporated in the SAPIEN Ultra 3 and the price premium. Can you just talk about the reception as you've marketed that in the early days? And how should we think about, I guess, the penetration of RESILIA tissue than the SAPEIN franchise in the U.S. in 2023 or in the coming quarters and into 2023?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joshua Jennings\", \"section_number\": 25, \"uuid\": \"2f315586-3f8c-4128-b861-535e9d2224b6\", \"speaker_title\": \"Analyst at Cowen & Company\"}"}]}, {"title": "Remarks by Larry Wood", "id": 49, "section": [{"id": 50, "text": "Sure. Well, we're very fortunate that our Surgical business has built a great brand around RESILIA and we get to follow that all of the brand work that they've been able to do. And so when you look at the Surgical side; I think the leading heart valve in the world now and that's largely based on the RESILIA tissue and how receptive people have been to the benefits that it brings. For SAPIEN 3 UR, that approval came a little bit earlier than we expected. We're super excited to add it to our SAPIEN platform.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 26, \"uuid\": \"f94a2644-57d4-4d78-972b-415a1b48a553\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 51, "text": "We're really just getting started in the launch. We have to scale up inventory and do some of the other things we need to do. But I think people are excited about it. And we are going for a price premium on that. We've increased our list price by about $1,500. Now people get rebates and there's different things around the country. So I don't know that I would model that in for everything. But I expect this is going to be a popular platform but it's going to take us a while to get it all rolled out.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 26, \"uuid\": \"f94a2644-57d4-4d78-972b-415a1b48a553\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Joanne Wuensch", "id": 52, "section": [{"id": 53, "text": "So I wanted to spend a little bit of time on hospital staffing because by our due diligence, it's getting better but not expected to get great anytime soon. So should we think about next year TAVR growth being more high single-digit growth in the U.S. versus double-digit growth? I just want to get my head around how to think about the lingering effects of this.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Joanne Wuensch\", \"section_number\": 28, \"uuid\": \"6e74746d-8fb1-4ef2-acc4-36d670db82d8\", \"speaker_title\": \"Analyst at Citigroup\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 54, "section": [{"id": 55, "text": "So. I can start us out, Joanne. So you're right, we don't expect staffing to be cured overnight. It's highly variable. As Larry indicated, just by the fact that we have almost half of the U.S. hospitals in TAVR that were growing at double digits. So there's a bunch of people not really suffering from staffing. And then again, there's another large swath of people that are really suffering from it. The conversations that we have with those folks in many cases say, oh, we're making progress, it's improving.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 29, \"uuid\": \"3d50cf00-6c7a-4358-bb3c-520f6e026799\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}, {"id": 56, "text": "Some say it might take them up to a year or 2 to improve it. There were probably widespread use of traveling nurses. That's had such a burden on the P&L of hospitals that they've curtailed that in long ways in many ways and been able to move beyond that. But this is going to be a process that takes some time. So does it hamper our growth next year? Probably some. I mean we do anticipate probably a tough winter, Joanne, just because of what's predicted here with COVID and the flu.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Michael Mussallem\", \"section_number\": 29, \"uuid\": \"3d50cf00-6c7a-4358-bb3c-520f6e026799\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}, {"id": 57, "text": "But beyond that, it's tough to say. We're going to be providing guidance at the investor conference, so you can get deep on that. And so we'll be prepared to go a little deeper at that time. Larry, you have anything to add?", "metadata_json": "{\"paragraph_number\": 3, \"speaker\": \"Michael Mussallem\", \"section_number\": 29, \"uuid\": \"3d50cf00-6c7a-4358-bb3c-520f6e026799\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 58, "section": [{"id": 59, "text": "Yes. I think it's important to remember, I mean, the patients are out there and they need to be treated. And the physicians are still very, very motivated to get these patients treated. And so they're frustrated as anybody else is. And I think hospitals are incentivized for doing procedures, not for not treating people. So I think everybody wants to get the situation resolved. I just think as hospitals have added staff, one of the first things they try to do, as Mike mentioned, is use the new staff to replace the traveling nurses to try to help out their own P&Ls.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 30, \"uuid\": \"60593532-4b67-4c98-b6ab-b3dcb7762b6d\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 60, "text": "And so that's maybe why we haven't seen as much lift from the staffing but hospitals are working super hard on this to get this resolved. It's going to take time because you can't just create nurses from scratch quickly but people are working really hard on getting this into a better place.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 30, \"uuid\": \"60593532-4b67-4c98-b6ab-b3dcb7762b6d\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Frederick Wise", "id": 61, "section": [{"id": 62, "text": "A couple of follow-up questions. And I apologize, it's hard to not focus on the U.S. growth numbers. Larry -- it is actually sort of a question for Larry, really but I'll just [indecipherable]. The -- I was -- expand on your comments on the U.S. referral chain. You talked about one aspect of getting patients treated, the imaging. But has COVID or anything about the current dynamics slowed patients showing up to clinics where they can be diagnosed in some way? Or is there some aspect that we can sort of focus on and imagine that it might get better sort of at the front of the patient gathering change?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Frederick Wise\", \"section_number\": 32, \"uuid\": \"c424a310-108f-4ba4-82b9-71857ef87321\", \"speaker_title\": \"Analyst at Stifel, Nicolaus & Company\"}"}, {"id": 63, "text": "And related to that, one of the thing I still can't quite understand and wrap my brain around is to I mean, stenosis are very -- patients are sick. How are they not being treated? And it's so hard to make imagine these people being in backlog. Maybe you could just talk around those points.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Frederick Wise\", \"section_number\": 32, \"uuid\": \"c424a310-108f-4ba4-82b9-71857ef87321\", \"speaker_title\": \"Analyst at Stifel, Nicolaus & Company\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 64, "section": [{"id": 65, "text": "Yes. Why don't I start, Rick and have Larry jump in. Yes, in the early days of the pandemic, I really do think it scared patients away from engaging in the system and getting treated. I think for the most part, we're in a different place now where the AS patients actually, they want to be treated. They're willing to go into the system but they're just finding the system grinding along slowly. And they're being pushed off and they're being postponed. And it's a multistep process. Maybe Larry, you can get a little bit deeper on that.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 33, \"uuid\": \"d24413ea-ee5a-4573-9521-5c89794d4e65\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 66, "section": [{"id": 67, "text": "Sure. Yes. I think referrals are increasing. I mean, what we hear anecdotally is that backlogs are growing at hospitals which would seem to indicate patients are still getting referred at least from what we hear from the physicians that we talk to. So I think that part of the system is starting to get better. But as I talked about earlier, there's just a multiple set of tests and screening and imaging that patients have to do before they get their TAVR. And I just don't think that system has come back to full health yet.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 34, \"uuid\": \"a64368bd-8f22-415a-81cd-4a4ac12d1d83\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 68, "text": "But I think we certainly have heard from centers that have said they kind of have to juggle patients with the more sick patients moving up the waiting list and then pushing the less sick patients down a little bit. But again, hopefully, this improves with time as staffing gets back to normalcy.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 34, \"uuid\": \"a64368bd-8f22-415a-81cd-4a4ac12d1d83\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Frederick Wise", "id": 69, "section": [{"id": 70, "text": "One last quick follow-up. Mike, you alluded to the buildup of the TMTT commercial team. Just curious, where are we -- and maybe specifically related to the PASCAL rollout, where are we, where are you hoping to be over the next few months as we approach '23?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Frederick Wise\", \"section_number\": 35, \"uuid\": \"af0f4f3e-2e0d-4b52-99f6-6ec0f46f0786\", \"speaker_title\": \"Analyst at Stifel, Nicolaus & Company\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 71, "section": [{"id": 72, "text": "Yes. Thanks, Rick. Yes, we're definitely building up that team and we're growing the team in Europe as well as the U.S. So we have Bernard right here. So Bernard, why don't you update us where we are?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 36, \"uuid\": \"3ebf8c18-38ac-4d68-9e15-7ea4ec08a138\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 73, "section": [{"id": 74, "text": "Okay. So maybe let me start with the U.S. We are obviously very pleased about having an early approval with PASCAL in the U.S. We are executing our plan which is training and expanding our field organization. We already started to train some physicians. We are negotiating some hospital contracts. We have done some few cases in the U.S. with great patient outcome. And you know that for us, it is our number one objective. So -- and we are initially focusing on the site that we are part of the clinical trial with us. So that's basically where we are in the U.S.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 37, \"uuid\": \"edbb788a-f71a-4ac8-970f-1ff60adcce31\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Philip Chickering", "id": 75, "section": [{"id": 76, "text": "First one is looking at the U.S. TAVR growth this quarter and I apologize for all the questions on this topic. Looking at the larger urban centers, are those centers growing at all or at that capacity is all the new growth coming from the smaller or newer centers?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Philip Chickering\", \"section_number\": 39, \"uuid\": \"13ea6c92-75a3-42ae-8eb9-ead7138e4c16\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 77, "section": [{"id": 78, "text": "Yes. Yes, I can start. It's quite -- it's really a mixed bag, Pito. But Larry, you want to make a few comments and [indecipherable].", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 40, \"uuid\": \"8d2df8f6-0bfe-414b-8144-354e0a870355\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 79, "section": [{"id": 80, "text": "It really is a mixed bag. I mean certainly, some of those centers are sort of more flattish. But we also have some of those big centers that are growing actually really well. So it's just really, really hard to generalize or to make broad overreaching comments. But as we said before, probably about half of our centers were growing in double digits. And -- but I think bigger centers maybe start a little bit more than some of the smaller centers. But again, I have big centers that are growing well. I have small centers that aren't growing. So these are just sort of some general comments.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 41, \"uuid\": \"6b503a8b-e29b-4d0f-a043-d3821f637a80\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Philip Chickering", "id": 81, "section": [{"id": 82, "text": "Okay. Fair enough. And then looking at the German market, its largest -- most mature market in Europe and I know that's sort of been COVID throughout the year. But just curious, how is the German market growing in 2022 and any colors or where that grew specifically in the third quarter?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Philip Chickering\", \"section_number\": 42, \"uuid\": \"59c99c9f-2854-49d5-a84e-66d8f9e52fcd\", \"speaker_title\": \"Analyst at Deutsche Bank\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 83, "section": [{"id": 84, "text": "So it kind of depends what we're talking about, Pito. So if you're talking about surgery or you're talking about TAVR or you're talking about the transcatheter mitral, they each have their own growth rates. In particular, in Germany, they have been hit by COVID. We tended to see it more in the ICUs in Germany, maybe more than any other country in Europe which tended to hurt our transcatheter mitral probably market growth a little bit more than some of the other segments. But I don't know, Larry or Bernard, do you have anything you want to add to that?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 43, \"uuid\": \"ea7bc2a8-3857-4338-bb59-bb7bfb27c329\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 85, "section": [{"id": 86, "text": "Yes, correct, Mike. We have seen a spike in COVID wave in -- specifically in Germany, mainly in October, late September, in October. So we don't know yet how it is going to resolve. Is it going to be an acute, only October? Is it going to get better in November? That's yet to be seen.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 44, \"uuid\": \"6e03ff73-17fa-43de-991b-2976665c0592\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Larry Wood", "id": 87, "section": [{"id": 88, "text": "Yes. I think generally speaking, Q3 in Europe is always a little bit tougher because we have the seasonality that we typically see with holiday vacations and those sorts of things. But we certainly have seen some challenges there but I would say the staffing issues are a little bit more scattered there than they are in the U.S. just more widespread.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 45, \"uuid\": \"f5003c95-9d55-4247-b6aa-eaf149b3110a\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 89, "section": [{"id": 90, "text": "But having said all those things that I know sound it all sounds pretty negative. You also have great big German centers with dedicated KOLs who are really good and really motivated. They're truly global leaders and key opinion leaders. These guys are just cranking. They're just going. We probably see more energy out of them than we've ever seen in the past.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 46, \"uuid\": \"c838d678-c045-4bf7-982a-039ffc9f26a2\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Cecilia Furlong", "id": 91, "section": [{"id": 92, "text": "I wanted to ask about PASCAL, PASCAL PRECISION in Europe, really what you've seen either from further standard penetration versus expanding new centers? How you're thinking about the growth drivers going forward, the bigger growth drivers? And then just turning to U.S. as well, the 2 PASCAL trials FMR and for TR, just if you could provide an update in terms of how you're thinking about recent progress with then in enrollment as well as kind of time lines to potential approval?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Cecilia Furlong\", \"section_number\": 48, \"uuid\": \"a7f5de2d-c0a9-4daa-ae10-d179fcb24232\", \"speaker_title\": \"Analyst at Morgan Stanley\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 93, "section": [{"id": 94, "text": "Okay. So we'll start out by talking about precision in Europe. And then we'll also comment on your question regarding the trials. So Bernard, do you want to...", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 49, \"uuid\": \"bff85da5-2284-4fa4-bb36-fd4db5a340e9\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 95, "section": [{"id": 96, "text": "Yes. So we began the conversion of center from PASCAL to the PASCAL PRECISION system and initial feedback from physician is very positive. And by the way, we got a great clinical outcome, patient outcome. So the physician appreciated the ease of use, the navigation improvement that the new system is bringing. So this year, we are very excited about it, even though we are at the beginning of it. So we see a lot of promise from this innovation with [indecipherable].", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 50, \"uuid\": \"52808e5b-9f33-4371-a968-b303559f896f\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 97, "section": [{"id": 98, "text": "And the other question was there any update related to the PASCAL TR or the functional patients that are being studied with PASCAL.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 51, \"uuid\": \"2e316da5-d392-454c-9bd6-c5a991dc08df\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 99, "section": [{"id": 100, "text": "So the two -- we are continuing [indecipherable] of these 2 pivotal studies with Class IID having completed enrollment. We believe that the sites are going to put more focus on these 2 remaining trials but we are continuing. It is going well. And I am going to provide you a little bit more update here during the investor conference.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 52, \"uuid\": \"7ee64b7a-049c-4dd9-a21e-c6964b7d32a8\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 101, "section": [{"id": 102, "text": "So the same trials that we're doing IID are probably doing IIF and IITR. So yes.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 53, \"uuid\": \"f048d4e0-70b4-48c0-b08f-7bbec4b9e442\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 103, "section": [{"id": 104, "text": "Mostly.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 54, \"uuid\": \"59daa6fc-3200-435e-ac02-1bf72c97a385\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Cecilia Furlong", "id": 105, "section": [{"id": 106, "text": "Great. And if I could just follow up really quickly your comments on EVOQUE in Europe and just the MDR process. Can you talk through what you're seeing today and really what kind of drove the about year push out, how you're thinking about just the process from your end going forward?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Cecilia Furlong\", \"section_number\": 55, \"uuid\": \"1edcdd15-02c4-40dd-aeb2-d50dd0a50ba3\", \"speaker_title\": \"Analyst at Morgan Stanley\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 107, "section": [{"id": 108, "text": "Yes. Thanks. We're very excited about the EVOQUE tricuspid valve replacement system and really think that it has the potential of being a game changer but Bernard, do you want to comment on MDR?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 56, \"uuid\": \"2e40bcbe-b6b4-4ece-862c-93716cd731a8\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 109, "section": [{"id": 110, "text": "So as you know, this MDR process is a new process. And like everyone, we are navigating this new process. And this new process is uncertain, specifically for breakthrough therapies like EVOQUE. We continue to be very pleased with the performance of EVOQUE. At London Valve, you are going to see additional data with more patients, longer follow-up. And so very much looking for this one. So for sure, disappointed by not being able to have an approval this year. But we are very excited about the promise of this technology. We are working very closely with our notified body, answering questions. And so we are very much looking forward to bring this important therapy to patients who have no options today.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 57, \"uuid\": \"b9f8370a-2d00-4363-b4fd-78a8c565fcd0\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Travis Steed", "id": 111, "section": [{"id": 112, "text": "I wanted a little more color on the TAVR guidance. It implies $850 million in Q4 which is down sequentially just wanted a better understanding of why down sequentially? And if that's a comment on both U.S. and OUS, you expect kind of both to be down quarter-over-quarter?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 59, \"uuid\": \"6c912880-cf81-4656-b5fe-88d87a2a197f\", \"speaker_title\": \"Analyst at Bank of America\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 113, "section": [{"id": 114, "text": "I'll start. Part of what we're experiencing is continuing foreign exchange headwinds. And so the $850 million incorporates sales from outside of the U.S. and in the U.S. And outside of the U.S., you've seen the euro and the yen just get weaker and weaker during the course of the year. And so that's part of what's hitting us in the fourth quarter.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 60, \"uuid\": \"30d81d5e-c493-49f7-a0f0-e2715e0a2697\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 115, "section": [{"id": 116, "text": "Yes. We actually expect more procedures, both in the U.S. and outside the U.S. in the fourth quarter.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 61, \"uuid\": \"2db6ed68-ecae-4db3-8a37-76839c2f9158\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Travis Steed", "id": 117, "section": [{"id": 118, "text": "Okay. Do you think -- so U.S. TAVR you expect to be up quarter-over-quarter?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 62, \"uuid\": \"53478cc8-7f96-43ea-8a59-267c99f0ca2b\", \"speaker_title\": \"Analyst at Bank of America\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 119, "section": [{"id": 120, "text": "The procedures will certainly be up. We're not prepared to predict the [indecipherable] foreign exchange.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 63, \"uuid\": \"461c7faa-d501-4e29-8305-b4d076c8cec4\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Travis Steed", "id": 121, "section": [{"id": 122, "text": "Okay. That's more a U.S. comment. But -- and I guess follow-up -- yes, you -- okay. And the follow-up question was on kind of on spending opex and margins for next year given some of the FX flow-through. I know the Street's got you at like 6 to 7 earnings growth next year. I just want to make sure big picture, we're accounting for all the puts and takes on the P&L as you consider models for 2023?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Travis Steed\", \"section_number\": 64, \"uuid\": \"ac4cb473-108e-408a-96fe-8012f81f989f\", \"speaker_title\": \"Analyst at Bank of America\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 123, "section": [{"id": 124, "text": "Yes. And again, I'm going to have to ask you to hold off for the detail on the ticking and tying until we get to New York on December 8. But we wanted to at least help you on modeling the top line and the gross margin. So top line, we're expecting, as we mentioned, similar headwinds to what we've seen this year. So call it over $200 million in headwinds. We had $270 million this year. And then you add to that lower gross margin. So we go down about 250 basis points from where we expect the full year this year which would take you to 77.5% just from a modeling perspective.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 65, \"uuid\": \"9079db16-c668-4873-9db6-6914048953ea\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}, {"id": 125, "text": "So the combination of those 2 things, flowing down the P&L should get you to at least a preliminary range of what to expect earnings per share. And like I said, we'll talk more about that [Phonetic].", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Scott Ullem\", \"section_number\": 65, \"uuid\": \"9079db16-c668-4873-9db6-6914048953ea\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 126, "section": [{"id": 127, "text": "Yes. Well, we had an inflated gross margin this year because of the impact of hedge contracts and that will largely go away.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 66, \"uuid\": \"a09eee71-e6db-405d-bb34-f24aa83a84f4\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Richard Newitter", "id": 128, "section": [{"id": 129, "text": "I just wanted to come back to a couple of points that you guys made about certain trends related to flu and COVID and then Japan specifically, just to be sure about what's getting better, what's just not getting worse and then what is getting worse into 4Q? And then you keep saying the winter months, it sounds like the early part of '23. So can you clarify what exactly you say, flu and COVID picking up being a tough winter? What regions? I want to make sure I understand where and what's factored into the guidance for that? And the same question on Japan, it sounds like that was getting a little better, you're through the worst of it but what's assumed in guidance specifically into 4Q? And how should we think beyond that?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Richard Newitter\", \"section_number\": 68, \"uuid\": \"33703df4-aa23-4bcc-9403-9c563e21f7f9\", \"speaker_title\": \"Analyst at Truist Securities\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 130, "section": [{"id": 131, "text": "All right. So there's several questions in there. Let's see if I'll take a shot at getting after a few of them. First, let me start with the end here. In Japan, we said, yes, Japan, we believe, is getting better. The seventh wave has peaked and is coming down. Will they have another wave in Japan? I don't know. Very difficult to say. We'd say, generally, the intelligence and this is particularly U.S. and Europe oriented, is that we expect it to be a rugged COVID and flu season.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 69, \"uuid\": \"e407c6f6-d17a-476c-8ba5-32c550c54497\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}, {"id": 132, "text": "And that -- we haven't fully experienced that yet that, that's probably more expected to come in November through January time frame. So yes, your question of could that also affect early 2023? Yes, it could. And some of this is just from the experience that we have all had around the world and a number of predictions about what's likely to happen based on the current variance. So I don't know, does that get that answer your question?", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Michael Mussallem\", \"section_number\": 69, \"uuid\": \"e407c6f6-d17a-476c-8ba5-32c550c54497\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Richard Newitter", "id": 133, "section": [{"id": 134, "text": "Yes. And I guess, what's assumed for that in your guide, did you assume that, that gets worse into the fourth quarter already?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Richard Newitter\", \"section_number\": 70, \"uuid\": \"77ac9940-49fd-4af3-a3c6-451ed280b8bd\", \"speaker_title\": \"Analyst at Truist Securities\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 135, "section": [{"id": 136, "text": "Rich, we assumed it in our guidance. And so there is an appropriate amount of expectation and I guess, conservatism that we are expecting continuing headwinds from respiratory illnesses, whether it's COVID or flu or something in between, we expect that that's going to continue to play a factor in the fourth quarter and into 2023.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 71, \"uuid\": \"b79c28ea-643a-4329-87a9-37015b8ba6d3\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Richard Newitter", "id": 137, "section": [{"id": 138, "text": "And if I could just 1 more. On I know that the -- that you said a 250 basis point year-over-year headwind. So that's clear. But as FX rates continue to go against you, I know that, that also pushes out the hedge impact into next year. So would that actually cause there to be a little bit even of a further pushout into '24 and maybe less or more mitigation of that falloff in '23? Am I thinking about that right?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Richard Newitter\", \"section_number\": 72, \"uuid\": \"367e0afd-de67-40d9-a3f5-278efbfea12e\", \"speaker_title\": \"Analyst at Truist Securities\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 139, "section": [{"id": 140, "text": "You are thinking about that right. Some of what we're seeing -- a lot of what we're seeing in 2023 is what we would have otherwise incurred in 2022. And similarly, we're going to see some FX benefit in the first part of there will then be a headwind in 2024.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 73, \"uuid\": \"9f81f92d-af3f-4812-a838-33db5ea2c23b\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 141, "section": [{"id": 142, "text": "All assumes that exchange rate stay where they are.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 74, \"uuid\": \"44857c9f-0946-4679-979d-ee0e2ee855ae\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Scott Ullem", "id": 143, "section": [{"id": 144, "text": "Yes, assumes current rate, exactly. I just want to clarify one thing. It's a 250 basis point headwind to gross margin, it's nearly a 5 percentage point headwind on the top line.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Scott Ullem\", \"section_number\": 75, \"uuid\": \"1181d128-45e3-475b-9981-f18e4b33afa0\", \"speaker_title\": \"Corporate Vice President & Chief Financial Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Adam Maeder", "id": 145, "section": [{"id": 146, "text": "Just two quick ones from me. First, just any update on the enrollment for the moderate AS trial or ALLIANCE trial? I think if I heard correctly, there's -- you saw some uptick in enrollment pace recently but I was hoping you could flesh that out a little bit more? And then second, how should we be thinking about the cadence of future data from the PASCAL IID study? Obviously, we got the initial data set at TCT but when should we expect additional readouts from that study?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Adam Maeder\", \"section_number\": 77, \"uuid\": \"5e26382a-0f13-4d7c-9688-4607f901389f\", \"speaker_title\": \"Analyst at Piper Sandler & Co.\"}"}]}, {"title": "Remarks by Larry Wood", "id": 147, "section": [{"id": 148, "text": "All right. This is Larry. So as it relates to ALLIANCE and PROGRESS, we just really got those trials going this year. And we have seen an acceleration in enrollment which is really encouraging for us to get these trials moving forward. And given the overall environment, you worry that clinical trials just really add on and it's a little bit counterintuitive but our trials are actually starting to enroll at accelerated rates. And so we're very encouraged by that. And I think people are excited about the X4 platform.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Larry Wood\", \"section_number\": 78, \"uuid\": \"39e81a35-ef08-46dc-98c8-93b8d1e3d5d9\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}, {"id": 149, "text": "And I think the moderate AS trial is potentially a groundbreaking trial in terms of how we think about this disease and what is the optimal way to treat it. And I think there's just been a lot of engagement from the physicians to study that in a rigorous randomized trial.", "metadata_json": "{\"paragraph_number\": 2, \"speaker\": \"Larry Wood\", \"section_number\": 78, \"uuid\": \"39e81a35-ef08-46dc-98c8-93b8d1e3d5d9\", \"speaker_title\": \"Corporate Vice President of Transcatheter Aortic Valve Replacement at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 150, "section": [{"id": 151, "text": "And Adam, your question about additional IID readouts is a good one. So far, this has really been an early readout of the Class IID which was sufficient to get U.S. approval but as we follow all of the patients in this trial for the full year, there will be additional data. Bernard, do you want to give us a sense of when that data might be available?", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 79, \"uuid\": \"f6546fe9-0cc5-472a-a927-7ac815c10996\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Bernard Zovighian", "id": 152, "section": [{"id": 153, "text": "Absolutely. You can expect to see additional data, more patients, more follow-up starting as early as next year.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Bernard Zovighian\", \"section_number\": 80, \"uuid\": \"f2c60871-e62f-4e5b-b20a-6c281c052c44\", \"speaker_title\": \"Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies at Edwards Lifesciences\"}"}]}, {"title": "Remarks by Michael Mussallem", "id": 154, "section": [{"id": 155, "text": "Okay. Well, thanks, everybody, for your continued interest in Edwards. Scott and the IR team and I certainly welcome any additional questions by telephone. Thanks so much.", "metadata_json": "{\"paragraph_number\": 1, \"speaker\": \"Michael Mussallem\", \"section_number\": 82, \"uuid\": \"dbfc92f2-d799-49b5-a518-fa945d271002\", \"speaker_title\": \"Chairman & Chief Executive Officer at Edwards Lifesciences\"}"}]}], "title": "Q&A for EW (Edwards Lifesciences) on 10/27/22 5:00 PM ET", "metadata_json": "{\"company_name\": \"Edwards Lifesciences\", \"company_ticker\": \"EW\", \"transcript_date\": \"10/27/22 5:00 PM ET\", \"section_type\": \"Q&A\", \"transcript_url\": \"https://www.marketbeat.com/earnings/transcripts/82156/\"}"}